Editas Medicine, Inc.
Financials
Valuation Metrics
Editas Medicine, Inc.'s Market Cap is $394M. At end of 2025 it was $182M. Ranked #2789 of 3,116 in US market (top 90%), #1226 of 1,472 on NASDAQ (top 83%), #222 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $394M | US#2,789/3,116 Sec#222/265 |
| Revenue | $46M | US#2,752/3,116 Sec#150/265 |
| Net Income | $-74M | US—/3,116 Sec—/265 |
| Total Assets | $237M | US#2,953/3,116 Sec#233/265 |
| Net Assets | $105M | US#2,789/3,116 Sec#211/265 |
| Employees | 87 | US#2,639/3,116 Sec#185/265 |
| Value | ||
| P/B | 3.74x | US#2,088/3,116 Sec#133/265 |
| P/S | 8.58x | US#2,683/3,116 Sec#116/265 |
| FCF Yield | -30.60% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -70.24% | US#2,743/3,116 Sec#187/265 |
| ROA | -31.15% | US#2,884/3,116 Sec#158/265 |
| Op. Margin | -178.78% | US#2,737/3,116 Sec#131/265 |
| Revenue Growth | 32.51% | US#379/3,116 Sec#59/265 |
| Financial Health | ||
| Debt Ratio | 125.46% | US#1,299/3,116 Sec#172/265 |
| Total Debt | $16M | US#2,779/3,116 Sec#194/265 |
| FCF | $-121M | US#2,676/3,116 Sec#161/265 |
| Cash | $182M | US#1,803/3,116 Sec#118/265 |
| Current Ratio | 3.19x | US#721/3,116 Sec#182/265 |
| Performance | ||
| 1Y Return | -16.72% | US#1,951/3,116 Sec#156/265 |
| 1M Return | -2.10% | US#497/3,116 Sec#36/265 |
| From 52W High | -34.90% | US#1,809/3,116 Sec#113/265 |
| 1Y MDD | -39.93% | US#2,206/3,116 Sec#145/265 |
| Trading | ||
| Volume | 1,031,678 shares | US#607/3,116 Sec#53/265 |
| Trading Value | $3M | US#2,337/3,116 Sec#186/265 |
| Per Share | ||
| EPS | $-0.48 | US—/3,116 Sec—/265 |
| BPS | $0.69 | US#2,728/3,116 Sec#210/265 |
Company Info
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.